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Abstract
Background: Cumulative evidence indicates that statins induce myotoxicity. However, the lack of understanding of
how statins affect skeletal muscles at the structural, functional, and physiological levels hampers proper healthcare
management. The purpose of the present study was to investigate the early after-effects of lovastatin on the slow-
twitch soleus (Sol) and fast-twitch extensor digitorum longus (EDL) muscles.
Methods: Adult C57BL/6 mice were orally administrated with placebo or lovastatin [50 mg/kg/d] for 28 days. At the
end of the treatment, the isometric ex vivo contractile properties of the Sol and EDL muscles were measured. Subtetanic
and tetanic contractions were assessed and contraction kinetics were recorded. The muscles were then frozen for
immunohistochemical analyses. Data were analyzed by two-way ANOVA followed by an a posteriori Tukey’s test.
Results: The short-term lovastatin treatment did not induce muscle mass loss, muscle fiber atrophy, or creatine kinase
(CK) release. It had no functional impact on slow-twitch Sol muscles. However, subtetanic stimulations at 10 Hz provoked
greater force production in fast-twitch EDL muscles. The treatment also decreased the maximal rate of force development
(dP/dT) of twitch contractions and prolonged the half relaxation time (1/2RT) of tetanic contractions of EDL muscles.
Conclusions: An early short-term statin treatment induced subtle but significant changes in some parameters of the
contractile profile of EDL muscles, providing new insights into the selective initiation of statin-induced myopathy in fast-
twitch muscles.
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Background
Statins are a class of drugs used to treat hypercholesterol-
emia by inhibiting HMG-CoA reductase, which is a rate-
limiting step in the biosynthesis of cholesterol. Statins are
effective for the primary and secondary prevention of
cardiovascular diseases, but their use is frequently
associated with statin-induced myopathy (SIM). SIM
encompasses myalgia, cramps, weakness, and even rhabdo-
myolysis [1–3]. While the pathophysiology of SIM is
heterogeneous and poorly understood, it appears to be
multifactorial and may involve multiple pathophysiological
defects, including genetic predisposition [4], early
mitochondrial dysfunctions [5–8], prenylated proteins
[9], the inhibition of protein geranylgeranylation [10],
ubiquinone depletion [11, 12], monocarboxylate trans-
porter 4 expression [13, 14], loss of t-tubular region
architecture [15, 16], altered membrane fluidity [17],
and immune-mediated necrotis [18].
Electrical stimulation causes Ca2+ release from the sarco-
plasmic reticulum (SR), triggering actin-myosin cross-
bridging and muscle contraction. Ca2+ is then rapidly
transported back into the SR lumen by SERCA [sarco
(endo) plasmic reticulum Ca2+ATPase], an ATP-dependent
Ca2+ pump, inducing muscle relaxation and preparing the
muscle for the next contraction. Myoplasmic Ca2+ also
regulates protein synthesis, protein degradation, and fiber
phenotype by controlling Ca2+-sensitive proteases,
transcription factors, and mitochondrial adaptations.
Mammalian skeletal muscles contain two SERCA isoforms.
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SERCA-1a is expressed in fast-twitch myofibers while
SERCA-2a is usually limited to slow-twitch myofibers [19].
SERCA pumps are defective in several forms of muscle
and heart disease, prolonging muscle relaxation and redu-
cing muscle force production [19, 20]. Impairment of the
sarcoplasmic reticulum (SR)/mitochondria Ca2+ release
system and the concomitant loss of Ca2+ homeostasis may
also be a crucial event leading to SIM [21–23]. A rise in
myoplasmic Ca2+ at rest triggers the calmodulin/calcine-
urin/Ca2+/calmodulin-dependent protein kinase II path-
way, activating NFATc1 and PGC-1α, two transcription
factors and modulators that facilitate the oxidative machin-
ery and slow-twitch phenotype [24, 25]. Interestingly, fast-
twitch myofibers, which contain three times more Ca2+ in
the SR than slow-twitch myofibers, are the first to dis-
appear in numerous forms of muscle disease and aging
[26–28]. These fibers appear to be especially prone to
SIM-induced dysfunction and necrosis [29–31]. The failure
to preserve physiological resting cytosolic Ca2+ concentra-
tions in SIM may potentially activate the calpain Ca2+−de-
pendant proteolytic pathway [21], repress protein synthesis
[32, 33], and stimulate the ubiquitin-proteasome system
[34, 35], favoring atrophy [33], myocellular damage [34]
and, ultimately, apoptosis [36, 37].
Since statins are widely prescribed and since SIM may
lead to the discontinuation of treatment, sometimes after
less than 2 weeks, we investigated the functional impact of
a short-term lovastatin treatment (28 days) on the ex vivo
contractile properties of slow-twitch Sol and fast-twitch
EDL muscles We also investigated the impact of a short-
term lovastatin treatment on muscle integrity, serum cre-
atine kinase release, and myosin phenotype in fast-twitch
EDL muscles. We showed that lovastatin caused subtle
early-stage functional changes in EDL muscles but not in
Sol muscles. The functional changes were not accompan-
ied by morphological or phenotypic changes.
Methods
Animals and experimental design
Male C57BL/6 mice (30–35 g) obtained from Charles
River Laboratories International (St-Constant, QC,
Canada) were housed one per cage, maintained in a 12 h
light/dark cycle, and given food and water ad libitum.
The mice were orally administered with placebo gelatin
gel or lovastatin [50 mg/kg/day; J&K scientific, Shanghai,
China] for 28 days (n = 8). Lovastatin was chosen for its
lipophilic nature, mid-range potency and clinical rele-
vance. The dosage is commonly used and was selected
because the HMG-CoA reductase activity and pharma-
cokinetics of lovastatin are different in rodents and
humans [38–40]. The Animal Care and Use Committee
of the CHUQ Research Centre approved all the
experiments, which complied with Canadian Council on
Animal Care guidelines.
Isometric contractile properties
After a 28-day lovasatin treatment and 24 h after the last
dose of lovastatin, the mice were injected with buprenor-
phine [0.1 mg/kg] for analgesia and pentobarbital sodium
[50 mg/kg] for anesthesia. The depth of analgesia/
anesthesia was monitored by pinching the Achilles ten-
don. The Sol and EDL muscles were completely resected
from the hindlimb, attached to a lever arm system (305B-
LR dual-mode; Aurora Scientific, Canada) controlled by
dynamic muscle control and data acquisition software
(Aurora Scientific Inc., Aurora, ON, Canada), and incu-
bated at 25 °C in an oxygenated Krebs-Ringer solution
supplemented with 2 mg/mL of glucose [41, 42]. During
the ex-vivo equilibrium period, contralateral muscles were
collected and the mice were euthanized by cervical dis-
location under anesthesia. Once the optimal length (Lo)
and twitch contractions had been determined, the muscles
were stimulated for 500 ms at 10, 20, 50, 80, 100, or
120 Hz to induce subtetanic and tetanic contractions.
Time-to-peak twitch tension (TPT, ms), half relaxation
time (1/2 RT), (ms), twitch tension (Pt, g), maximum tet-
anic tension (P0, g), and peak rate of tension development
(dP/dT) values were also recorded. At the end of the con-
tractile property measurements, the lengths of the muscles
were measured. The tendons were removed, and the mus-
cles were weighed, embedded and frozen in isopentane
cooled in liquid nitrogen, and stored at −80 °C until used
for the immunohistochemical assays. The mice were then
euthanized by cervical dislocation under anesthesia.
Enzymatic assays and immunohistochemical experiments
Serum creatine kinase activity was determined using a col-
orimetric assay kit (BioVision, USA). To assess muscle at-
rophy, the Sol and EDL muscles were perpendicularly
sectioned (10 μm), stained with hemotoxylin and eosin
(H&E; Sigma-Aldrich, USA), and observed using an
inverted light microscope, (Nikon, Canada). Cross-
sectional areas (CSA) were analyzed using ImageJ software
1.46r (NIH, USA). Myosin heavy chain (MyHC) I and
MyHC II antibodies (Leica Biosystems, Canada) were used
to determine changes in fast and slow phenotypes in EDL
muscles. Approximately 100 myofibers per muscle were
quantified. All values are expressed as means ± standard
errors of the mean. Data were analyzed by two-way
ANOVA (InStat software, v.3). When a significant F ratio
was obtained, an a posteriori Tukey’s test was performed.
The level of significance was set at p < 0.05.
Results
To investigate the effect of lovastatin on muscle atrophy,
the masses and CSA of Sol and EDL muscles from placebo
and statin-treated mice were determined. The 28-day sta-
tin treatment had no significant effect on muscle mass or
CSA values (Tables 1 and 2). Serum creatine kinase levels,
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which are a biomarker of muscle damage, were below the
limit of detection. Hematoxylin and eosin (H&E) staining
revealed no significant muscle damage in the control and
statin-treated mice (Fig. 1).
To characterize the impact of lovastatin on muscle
function, we measured the ex vivo contractile properties
of the Sol and EDL muscles. The control and statin-
treated slow-twitch Sol muscles had similar contraction
magnitude and kinetics values (Table 1, Fig. 2a, c, d).
The absolute force production of the Sol muscles from
the statin-treated mice tended to increase (p < 0.06)
when stimulated at 50, 80, 100 and 120 Hz (Fig. 2a).
However, when the force production was normalized
with mass, the Sol muscles from the control and statin-
treated mice displayed similar levels of specific tetanic
force production (Table 1). The lovastatin treatment did
not affect the TPT, Pt/P0, or Pt ½RT values (Table 2) of
fast-twitch EDL muscles. However, the treatment signifi-
cantly decreased the maximal rate of tension generation
(dP/dT) for twitch contractions (Pt) by 22.4 % (Fig. 2c)
and significantly prolonged the ½ RT for tetanic
contractions (P0) by 48.7 % in fast-twitch EDL muscles
from statin-treated mice compared to EDL muscles from
the control mice (Fig. 2d). In addition, the force produc-
tion at 10 Hz of EDL muscles from the statin-treated
mice was significantly higher (36.7 % gain) than EDL
muscles from the control mice (Fig. 2b). Despite the ten-
dency for force to increase at 1 and 20 Hz (p < 0.06 stat-
istical trend), there were no significant differences at
higher stimulation frequencies (50–120 Hz) (Fig. 2b).
Since these changes in the contractile profiles were
suggestive of changes in muscle phenotype, we quanti-
fied the percentage of fast MyHC isoform. The changes
in the contractile profile of EDL muscles were not asso-
ciated with significant changes in the proportion of fi-
bers expressing fast MyHC isoform (98 % fast MyHC in
EDL muscles) following the lovastatin treatment (data
not shown).
Discussion
SIM has major social and economic consequences. The
lack of understanding of how statins impair muscle
function at the molecular, cellular, and physiological
levels creates numerous barriers to effective treatment
[2]. SIM can result in the discontinuation of treatment,
leaving specific patients at risk of potential adverse car-
diovascular events [43]. The onset of SIM is most likely
multifactorial, resulting in multiple physiological impair-
ments in patients with ill-defined musculoskeletal condi-
tions. We showed that a short-term lovastatin treatment
induces subtle but significant changes in the contractile
profile of fast-twitch EDL muscles.
We also showed that a short-term 28-day lovastatin treat-
ment did not affect the morphology, integrity, or maximal
force output of slow-twitch Sol and fast-twitch EDL mus-
cles. However, the force production of subtetanic contrac-
tions at 10 Hz was significantly higher while the ½ RT at P0
of EDL muscles was prolonged in statin-treated mice com-
pared to control mice. From a physiological standpoint, a
prolonged ½ RT at P0 should favor a longer lasting Ca
2+
transient, leading to a gain of force production at a low fre-
quency stimulation (10 Hz). Furthermore, the prolonged ½
RT in fast-twitch EDL muscles also suggested that Ca2+ re-
uptake by the SR is impaired. Ca2+ reuptake is almost ex-
clusively mediated by SERCA-1a in fast-twitch fibers.
SERCA is critical for Ca2+ homeostasis and reuptake by the
SR following contractions, allowing cytosolic Ca2+ concen-
trations to return to baseline levels and enabling muscle re-
laxation [19, 44]. Consistent with our results and a role for
statins in the regulation of Ca2+ handling, chronic 2-
month-long treatments of rats with fluvastatin [20 mg/kg]
increase the resting cytosolic Ca2+ concentration of EDL
muscle fibers by 60 % but have no impact on muscle integ-
rity and grip strength [21]. Pierno et al. (1999) also reported
that EDL muscles from simvastatin-treated rats require less
Table 1 Morphology and contractile properties of Sol muscles
Measure Placebo Lovastatin
Muscle mass; (mg) 10,79 ± 0,10 10,92 ± 0,76
Cross-sectional area; (μm2) 1101,98 ± 78,55 1146,79 ± 88,46
Twitch tension Pt; (g) 3,25 ± 0,28 3,81 ± 0,51
Maximal tetanic force P0; (g) 22,72 ± 1,11 25,72 ± 0,45
p=0.053
Specific force sP0; (g/mg) 2,18 ± 0,09 2,38 ± 0,09
Pt/P0 0,14 ± 0,01 0,14 ± 0,02
Time to peak tension TPT; (ms) 52,14 ± 2,15 47,83 ± 3,28
1/2 RT at Pt; (ms) 47,14 ± 2,59 47,01 ± 2,30
The treatment with lovastatin [50 mg/kg/day] for 28 days had the tendency
(0,05 < p < 0,06) to increase the maximum tetanic force (P0) of Sol muscles.
Data are expressed as means ± SE, n = 8 mice for each experimental group.
The level of significance was set at *p < 0.05
Table 2 Morphology and contractile properties of extensor
digitorum longus muscles
Measure Placebo Lovastatin
Muscle mass; (mg) 11,89 ± 0,76 12,71 ± 0,10
Cross-sectional area; (μm2) 1154,36 ± 115,02 1285,96 ± 64,05
Twitch tension Pt; (g) 4,82 ± 0,37 6,25 ± 0,63 p=0.088
Maximal tetanic force P0; (g) 28,83 ± 2,23 30,37 ± 2,67
Specific force sP0; (g/mg) 2,45 ± 0,16 2,39 ± 0,20
Pt/P0 0,17 ± 0,01 0,20 ± 0,01
Time to peak tension TPT; (ms) 27,71 ± 1,54 29,83 ± 2,62
1/2 RT at Pt; (ms) 14,43 ± 1,14 17,00 ± 1,00
The treatment with lovastatin [50 mg/kg/day] for 28 days had the tendency
(0,05 < p < 0,09) to increase the twitch tension (Pt) of EDL muscles. Data are
expressed as means ± SE, n = 8 mice for each experimental group. The level of
significance was set at *p < 0.05
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Fig. 1 Cross-sections of soleus and extensor digitorum longus muscles stained with hematoxylin and eosin. There were no significant differences in
the structure and histologic features of Sol and EDL muscles following placebo or lovastatin [50 mg/kg/day] treatments. Scale bar = 100 μm
Fig. 2 Contractile properties of soleus and extensor digitorum longus muscles in placebo and lovastatin-treated mice. Frequency-force relationships
for Sol (a) and EDL muscles (b). Maximal rate of force development of twitch contractions (c) and half-relaxation time of tetanic contractions (d)
in Sol or EDL muscles following placebo or lovastatin [50 mg/kg/day] treatments for 28 days. The absolute force production of the Sol muscles
from the statin-treated mice tended to increase (p < 0.06) when stimulated at 50, 80, 100 and 120 Hz. The treatment significantly decreased the
maximal rate of tension generation (dP/dT) for twitch contractions (Pt) by 22.4 % and significantly prolonged the ½ RT for tetanic contractions
(P0) by 48.7 % in fast-twitch EDL muscles from statin-treated mice compared to EDL muscles from the control mice. Data are expressed as means
± SE, n = 8 for each experimental group. The level of significance was set at *p < 0.05
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depolarization to contract, suggesting that they contain
higher levels of cytosolic Ca2+ [45]. Liantonio et al. (2007)
proposed that mitochondria are responsible for the earlier
event, with a subsequent and larger Ca2+ leakage from SR
stores, and that extracellular Ca2+ channels play a negligible
role in the increase in cytosolic Ca2+. Applying simvastatin
to human skeletal muscle fibers triggers a wave of cytosolic
Ca2+ originating from the SR Ca2+ store, while ryanodine
and SERCA inhibitors almost completely abolish the in-
crease in cytosolic Ca2+ [46]. These findings indicated that
the loss of Ca2+ homeostasis associated with SIM may be
caused by the release of Ca2+ from mitochondria and/or
the SR store [21, 22, 46]. The prolonged ½ RT and gain of
force at a low stimulation frequency provide additional sup-
port for the notion that Ca2+ handling is impaired, espe-
cially in fast-twitch muscles, following statin treatments.
We also showed that the maximum dP/dT, i.e. the peak
rate of force development, is 22.4 % lower in EDL muscles
from statin-treated mice. A decrease in dP/dT should be
associated with a change in muscle phenotype from fast-
to slow-twitch. In rats, a simvastatin-treatment induces a
15 % shift from the fast MyHC IIb/x to the slower MyHC
IIa phenotype, which is associated with a loss of power
output (−41 %) and a reduced shortening velocity (−23 %),
with no change in isometric force or CK levels [47]. How-
ever, we did not detect any phenotypic changes in EDL
muscles after the 28-day lovastatin treatment. Since chol-
esterol plays a pivotal role in the composition, fluidity, and
integrity of the cell membrane, it is possible that statin
treatments alter the compliance/rigidity of the muscle
membrane, thus decreasing dP/dT. In other words, the
contractile component shortens and stretches the elastic
component (membrane, extracellular matrix, tendon) by
the same amount during contractions. A more compliant
membrane/extracellular matrix in statin-treated mice
would lower dP/dT. Accordingly, statins cause a deterior-
ation of the biomechanical properties of the Achilles ten-
don [48] and may be a risk factor for muscle and tendon
ruptures and tendinopathies [49, 50]. Statins have thus
pleiotropic properties, but the exact mechanism by which
they decrease dP/dT requires further investigation.
Conclusions
Our results provide additional support for the observation
that statin treatments have an impact on fast-twitch mus-
cles but have no effect on the function of slow-twitch
muscles. Fast-twitch myofibers are also more vulnerable
to dysfunction in several forms of muscle disease [51–53].
The changes in the contractile profiles of EDL muscles
have also been observed in young and healthy mice
treated with a physiological dose of statin. Statins are often
prescribed to elderly patients, who are often sarcopenic
and undergo a gradual change toward a slow-myofiber
phenotype [54, 55]. Would these changes in contractile
properties be greater in patients with chronic conditions?
Would this shift toward slow phenotype increase the risk
of falls given that explosive bursts of strength and power
are needed to prevent falls? In this context, it would be
relevant to determine whether statin treatments exacer-
bate aging-induced muscle dysfunction and whether the
prevalence of SIM is higher in patients with chronic phys-
ical conditions. Further animal and human investigations
are warranted to determine how statins induce SIM and
muscle dysfunction.
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